Clinical trial
A Study Evaluating the Efficacy and Safety of Sunitinib With or Without…
NCT00491738 · Genentech, Inc., Industry · Terminated
Key facts
| NCT number | NCT00491738 |
|---|---|
| Title | A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R) |
| Official title | A Multicenter, Phase II, Randomized, Blinded, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Sutent With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Renal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | bevacizumab, sunitinib, placebo |
| Enrollment | 16 |
| Start date | Aug 1, 2007 |
| Primary completion | Jan 1, 2008 |
| First posted | Jun 26, 2007 |
| Last update posted | Apr 10, 2009 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: